Trade Report: Today, UBS Asset Management Americas Inc. Reached $94,667,000 position of Alexion Pharmaceuticals Inc. (ALXN)

Today, UBS Asset Management Americas Inc. Reached $94,667,000 position  of Alexion Pharmaceuticals Inc. (ALXN)

UBS Asset Management Americas Inc. lowered its stake in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 11.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 772,545 shares of the biopharmaceutical company’s stock after selling 96,884 shares during the period. UBS Asset Management Americas Inc.’s holdings in Alexion Pharmaceuticals were worth $94,667,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Investors Capital Advisory Services raised its stake in Alexion Pharmaceuticals by 0.7% in the second quarter. Investors Capital Advisory Services now owns 1,996 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 14 shares in the last quarter. Navellier & Associates Inc raised its stake in shares of Alexion Pharmaceuticals by 0.5% in the second quarter. Navellier & Associates Inc now owns 3,477 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 17 shares in the last quarter. Bremer Trust National Association raised its stake in shares of Alexion Pharmaceuticals by 0.5% in the third quarter. Bremer Trust National Association now owns 5,478 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 26 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in shares of Alexion Pharmaceuticals by 0.8% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 5,691 shares of the biopharmaceutical company’s stock worth $598,000 after buying an additional 43 shares in the last quarter. Finally, MSI Financial Services Inc raised its stake in shares of Alexion Pharmaceuticals by 1.0% in the third quarter. MSI Financial Services Inc now owns 4,290 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 44 shares in the last quarter. Institutional investors and hedge funds own 94.85% of the company’s stock.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) opened at 119.38 on Tuesday. Alexion Pharmaceuticals Inc. has a 12-month low of $110.56 and a 12-month high of $193.45. The company’s 50-day moving average is $122.56 and its 200 day moving average is $128.72. The stock has a market capitalization of $26.76 billion, a PE ratio of 72.79 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The business earned $799 million during the quarter, compared to analyst estimates of $787.07 million. During the same period in the prior year, the business earned $1.16 EPS. The company’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, equities research analysts expect that Alexion Pharmaceuticals Inc. will post $4.64 earnings per share for the current fiscal year.

ALXN has been the topic of a number of research analyst reports. Vetr lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 target price on the stock. in a research report on Wednesday, August 3rd. Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Thursday, September 22nd. Citigroup Inc. raised their target price on shares of Alexion Pharmaceuticals from $154.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, September 20th. Brean Capital initiated coverage on shares of Alexion Pharmaceuticals in a research report on Tuesday, October 4th. They issued a “buy” rating and a $221.00 target price on the stock. Finally, Goldman Sachs Group Inc. upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $158.00 target price on the stock in a research report on Friday, October 28th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $173.36.

In related news, EVP Carsten Thiel sold 4,584 shares of the stock in a transaction dated Friday, October 14th. The shares were sold at an average price of $120.28, for a total value of $551,363.52. Following the completion of the transaction, the executive vice president now directly owns 32,741 shares in the company, valued at approximately $3,938,087.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Leonard Bell sold 1,300 shares of the stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $135.28, for a total transaction of $175,864.00. Following the completion of the transaction, the director now owns 406,589 shares of the company’s stock, valued at $55,003,359.92. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by company insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Related posts

Leave a Comment